Skip to main content
Article thumbnail
Location of Repository

Regulation of the procoagulant activity of platelets and platelet-derived microparticles

By Hassan A.A. Hamali


Procoagulant microparticles (MPs) in the circulation are increasingly recognized as playing a role in haemostasis and inflammation and may prove useful biomarkers for clinical studies. Platelets are known to generate MPs in response to stimulation, and platelet-derived MPs (PDMPs) form the majority of the MPs found in the normal circulation and can be elevated in a number of disease states. The current study has focused on the procoagulant activity of platelets and PDMPs following stimulation with the collagen-mimetic peptide CRP-XL. Their activity in accelerating thrombin generation can be accurately measured by the Calibrated Automated Thrombogram (CAT) assay using 1pM TF reagent to initiate the reaction, with the finding that plasma from patients with chronic renal disease has significant thrombin generation due to increased procoagulant activity of MPs. Conversely premature MI patients in a stable condition have thrombin generation comparable to matched healthy control. In all subjects, removal of MPs from plasma by filtration (>0.2 μm) eliminates this procoagulant activity, indicating the importance of MP size in driving the procoagulant response. The procoagulant activity of activated platelets and PDMPs showed a strong correlation with annexin-V binding measured using flow cytometry. Comparison of the regulatory mechanism of the procoagulant activity of platelet and PDMPs upon activation with platelets undergoing apoptosis showed that although both activation and apoptosis resulted in exposure of the procoagulant surface, apoptotic platelets did not release procoagulant MPs or show any markers of activation such as P-selectin expression, fibrinogen binding or aggregation. Reactive oxygen species (ROS) are generated during platelet activation or apoptosis mainly through the NADP(P)H oxidase pathway. The procoagulant activity of platelets and PDMPs was significantly attenuated (as measured by thrombin generation and annexin-V binding) by inhibition of the NAD(P)H oxidase pathway by apocynin, which had similar inhibition on other platelet responses including on 12-HETE generation, TxB2 production and aggregation. However antioxidants only inhibited apoptosis-induced platelet procoagulant activity. These data demonstrate significant involvement of ROS in platelet procoagulant activity induced by both activation and apoptosis and suggest the involvement of lipid peroxidation during apoptosis

Publisher: University of Leicester
Year: 2011
OAI identifier:

Suggested articles


  1. (2000b) The endothelial cell protein C receptor.
  2. (1995). 3,5-Di-t-butyl-4-hydroxytoluene (BHT) and probucol stimulate selectively the reaction of mammalian 15-lipoxygenase with biomembranes.
  3. (2001). A cell-based model of hemostasis.
  4. (2006). A cell-based model of thrombin generation.
  5. (1999). A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets.
  6. (2008). A critical role for extracellular protein disulfide isomerase during thrombus formation in mice.
  7. (2003). A crucial role of glycoprotein VI CH 9: References for platelet recruitment to the injured arterial wall in vivo.
  8. (1998). A dual thrombin receptor system for platelet activation.
  9. (2009). A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways.
  10. (2002). A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity.
  11. (1999). A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase.
  12. (2010). A multicolor flow cytometric assay for measurement of platelet-derived microparticles.
  13. (1987). A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia.
  14. (1989). A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion.
  15. (2001). Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis.
  16. (1999). Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.
  17. (1990). Activation of human factor V by factor Xa and thrombin.
  18. (1998). Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation.
  19. (2004). Active tissue factor in blood?
  20. (1994). Adhesion receptor activation of phosphatidylinositol 3-kinase. von Willebrand factor stimulates the cytoskeletal association and activation of phosphatidylinositol 3-kinase and pp60c-src in human platelets.
  21. (1994). ADP causes partial degranulation of platelets in the absence of aggregation.
  22. (2003). Advantages of fast-acting ADP receptor blockade in ischemic heart disease.
  23. (1964). An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier.
  24. (2010). An Important Role for
  25. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
  26. (1996). Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.
  27. (1996). Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion.
  28. (2010). Annexin V binding to platelets is agonist, time and temperature dependent.
  29. (1996). Annexin V inhibition of factor IXacatalyzed factor X activation on human platelets and on negativelycharged phospholipid vesicles.
  30. (1998). Anti-inflammatory drugs and their mechanism of action.
  31. (2001). Antibody against platelet membrane glycoprotein VI in a patient with systemic lupus erythematosus.
  32. (1999). Antioxidant enzymes and human diseases.
  33. (2010). Antiplatelet therapies for the treatment of cardiovascular disease.
  34. (2001). Apoptosis as a determinant of atherothrombosis.
  35. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.
  36. (2003). Apoptotic activity in stored human platelets.
  37. (2010). Application of dynamic light scattering to the measurement of microparticles.
  38. (2000). Aspects of cardiovascular burden in pre-dialysis patients.
  39. (1989). Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.
  40. (2009). Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan.
  41. (2002). Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling.
  42. (1972). Asymmetrical lipid bilayer structure for biological membranes.
  43. (1998). Atherogenic Lipoproteins Support Assembly of the Prothrombinase Complex and Thrombin Generation: Modulation by Oxidation and Vitamin
  44. (2009). Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles.
  45. (1984). ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes.
  46. (1999). BCL-2 family members and the mitochondria in apoptosis.
  47. (2007). Bcl-2 family proteins are essential for platelet survival.
  48. (2011). Bcl-xL inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.
  49. (1990). Binding of annexin-V placntal anticoagulant protein to platelets evidenace for phosphotidylserine exposure in the procoagulant respone of activated platelets.
  50. (1990). Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers.
  51. (1999). Biochemistry and physiology of blood coagulation.
  52. (1987). Biosynthesis of major platelet proteins in human blood platelets.
  53. (1996). Blood clotting in minimally altered whole blood.
  54. (1991). Blood platelet count and function are related to total and cardiovascular death in apparently healthy men.
  55. (1999). Blood-borne tissue factor: another view of thrombosis.
  56. (2009). Calcium signaling in platelets.
  57. (2010). Calcium-dependent phospholipid scrambling by TMEM16F.
  58. (2009). Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. Thromb Res,
  59. (2003). Calibrated automated thrombin generation measurement in clotting plasma.
  60. (2006). Calmodulin interacts with the platelet ADP receptor P2Y1.
  61. (1996). Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury.
  62. (1999). Can antioxidant vitamins materially reduce oxidative damage in humans?
  63. (2002). Carbonyl toxicology and Alzheimer's disease.
  64. (1998). Caspases: enemies within.
  65. (2004). Cell death: critical control points.
  66. (1997). Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant.
  67. (2009). Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost,
  68. (2007). Cellular origins and CH 9: References thrombogenic activity of microparticles isolated from human atherosclerotic plaques.
  69. (1983). Changes in membrane phospholipid distribution during platelet activation.
  70. (2001). Channeling during prothrombin activation.
  71. (2004). Characterisation and studies of T-lymphoblastoid procogulant actvity.
  72. (2009). Characterization of novel radicals from COX-catalyzed arachidonic acid peroxidation.
  73. (2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
  74. (2010). Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes.
  75. (2005). Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.
  76. (2006). Circulating platelet-derived microparticles in systemic lupus erythematosus -Association with increased thrombin generation and procoagulant state. Thrombosis and Haemostasis,
  77. (2006). Circulating platelet-derived microparticles in systemic lupus erythematosus. CH 9: References Association with increased thrombin generation and procoagulant state.
  78. (2002). Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients.
  79. (2009). Circulating procoagulant microparticles in patients with venous thromboembolism.
  80. (2000). Circulating tissue factor and thrombosis.
  81. (2004). Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition.
  82. (1992). Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation.
  83. (1998). Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.
  84. (1981). Coagulation factor III (tissue factor) interaction with phospholipid vesicles induced by cadmium: characterization of the reconstituted protein-membrane complex.
  85. (1991). Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils.
  86. (1985). Comparison of the abilities of synthetic and platelet-derived membranes to enhance thrombin formation.
  87. (2004). Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
  88. (2001). Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization. New England
  89. (1988). Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity.
  90. (2004). Complementindependent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway.
  91. (2001). Complementindependent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia.
  92. (1991). Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation.
  93. (2008). Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thromblogram parameters.
  94. (1985). Coronary no-reflow is caused by CH 9: References shedding of active tissue factor from dissected atherosclerotic plaque.
  95. (2002). Correlation of Antiphospholipid Antibody Recognition with the Structure of Synthetic Oxidized Phospholipids.
  96. (2008). Correlations between platelet-derived microvesicles and thrombin generation in patients with coronary artery disease.
  97. (2008). Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis.
  98. (2007). Cyclosporine enhances platelet procoagulant activity.
  99. (2004). Cysteine/cystine couple is a newly recognized node in the circuitry for biologic redox signaling and control.
  100. (1998). Death receptors: signaling and modulation.
  101. (1994). Decreased membrane phospholipid packing and CH 9: References decreased cell size precede DNA cleavage in mature mouse B cell apoptosis.
  102. (1999). Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
  103. (2010). Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing.
  104. (2010). Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay.
  105. (1995). Determinants of plasma factor VIIa levels in humans.
  106. (2000). Different role of platelet glycoprotein GP Ia/IIa in platelet contact and activation induced by type I and type III collagens.
  107. (1991). Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation.
  108. (1990). Direct detection of activated platelets and platelet-derived microparticles in humans.
  109. (2002). Distinct glycoprotein Ib/V/IX and integrin alpha IIbbeta 3-dependent calcium signals cooperatively regulate platelet adhesion under flow.
  110. (2006). Disulfide isomerization switches tissue factor from coagulation to cell signaling.
  111. (2005). Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?
  112. (2006). Early caspase-3 activation independent of apoptosis is required for cellular function.
  113. (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.
  114. (2007). Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study.
  115. (2008). Effects of apoptosis and lipid peroxidation on T-lymphoblastoid phospholipiddependent procoagulant activity.
  116. (2002). Effects of glucocorticoids on generation of reactive oxygen species in platelets.
  117. (2006). Effects of storage-induced platelet microparticles on the initiation and propagation phase of blood coagulation.
  118. (2009). Eicosanoids: generation and detection in mammalian cells.
  119. (2007). Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.
  120. (1991). Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes.
  121. (2000). Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.
  122. (1993). Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias.
  123. (1993). Endocytosis of fibrinogen into megakaryocyte and platelet alphagranules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa).
  124. (2009). Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment.
  125. (2003). Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis.
  126. (1998). Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients.
  127. (2003). Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome.
  128. (2005). Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets.
  129. (1997). Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases.
  130. (2005). Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
  131. (2006). Evidence for activation of tissue factor by an allosteric disulfide bond.
  132. (1988). Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporintreated renal allograft recipients.
  133. (1984). Evidence that three adhesive proteins interact with a common recognition site on activated platelets.
  134. (1985). Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3. Thromb Res,
  135. (1995). Expression of constitutive endothelial nitric oxide synthase in human blood platelets.
  136. (2006). Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome.
  137. (1991). Factor XI activation in a revised model of blood coagulation.
  138. (2003). Fc Rgamma -independent signaling by the platelet collagen receptor glycoprotein VI.
  139. (1982). First proof that vitamin E is major lipid-soluble, chain-breaking antioxidant in human blood plasma.
  140. (2001). Flavonoid antioxidants.
  141. (2011). Flow cytometric analysis of microparticle phenotype and their role in thrombin generation.
  142. (2010). Flow cytometric detection of endothelial microparticles (EMP): effects of centrifugation and storage alter with the phenotype studied.
  143. (1981). Flow cytometric electronic direct current volume and radiofrequency impedance measurements of single cells and particles.
  144. (2008). Flow cytometric measurement of microparticles: pitfalls and protocol modifications.
  145. (2004). Flow-cytometric analysis of plateletmembrane glycoprotein expression and platelet activation.
  146. (1995). Flow-related platelet deposition on subendothelium.
  147. (1998). Free radical stimulation of tyrosine kinase and phosphatase activity in human peripheral blood mononuclear cells.
  148. (2008). From vulnerable plaque to atherothrombosis.
  149. (1999). Function of glycoprotein VI and integrin alpha2beta1 in the procoagulant response of single, collagen-adherent platelets.
  150. (2004). Functional role of NADPH oxidase in activation of platelets.
  151. (1997). Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets.
  152. (2004). Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
  153. (2001). Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen.
  154. (1998). Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the plateletactivating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not.
  155. (1997). Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain.
  156. (2006). Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo.
  157. (1989). GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies.
  158. (2005). GPVI and integrin alphaIIb beta3 signaling in platelets.
  159. (2007). GPVI potentiation of platelet activation by thrombin and adhesion molecules independent of Src kinases and Syk. Arterioscler Thromb Vasc
  160. (2005). How neutrophils kill microbes.
  161. (2005). Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI.
  162. (2003). Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner.
  163. (2000). Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation.
  164. (2007). Human platelets synthesize and express functional tissue factor.
  165. (2007). Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation.
  166. (2001). Identification of the platelet ADP receptor targeted by antithrombotic drugs.
  167. (2002). Impairment of vascular responses to reactive hyperemia and nitric oxide in chronic renal failure.
  168. (1989). In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma.
  169. (2004). Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome.
  170. (2008). Increased level of platelet microparticles in survivors of myocardial infarction.
  171. (2005). Increased levels of procoagulant factors associated with increased potential for thrombin generation in patients with premature myocardial infarction. Joirnal of thrombosis and haemostasis,
  172. (2004). Induction of microparticle- and cellassociated intravascular tissue factor in human endotoxemia.
  173. (2001). Inflammation and atherothrombosis.
  174. (2008). Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma.
  175. (2003). Influence of flow on inhibiton of platelet dependent thrombin generatiomn by an antiGPIIb/IIIa.
  176. (2006). Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study.
  177. (2004). Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans.
  178. (1991). Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: blockade of aggregation and secretion by an aspirin-insensitive mechanism.
  179. (2003). Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist.
  180. (1995). Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. Arterioscler Thromb Vasc
  181. (2004). Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of CH 9: References plasma: subject-dependent variation in thrombogram characteristics.
  182. (1995). Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity.
  183. (2002). Interaction of calmodulin with the cytoplasmic domain of platelet glycoprotein VI.
  184. (2005). Intracellular proatherogenic events and cell adhesion modulated by extracellular thiol/disulfide redox state.
  185. (1999). Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase
  186. (1979). Isolated deficiency of platelet procoagulant activity.
  187. (2008). Level, distribution and correlates of platelet-derived CH 9: References microparticles in healthy individuals with special reference to the metabolic syndrome.
  188. (2003). Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice.
  189. (2004). Lipid antioxidant, etoposide, inhibits phosphatidylserine externalization and macrophage clearance of apoptotic cells by preventing phosphatidylserine oxidation.
  190. (1995). Lipid peroxidation by activated platelets: a possible link between thrombosis and atherogenesis.
  191. (1969). Lipid peroxidation in aging platelets.
  192. (1994). Lipid peroxidation in platelet concentrates: effects of leukocyte removal by filtration.
  193. (1994). Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein Ib alpha.
  194. (1989). Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.
  195. (2001). Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice.
  196. (2007). Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus.
  197. (2011). Measurement of circulating
  198. (2007). Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
  199. (2009). Measurement of phosphatidylserine exposure during storage of platelet concentrates using the novel probe lactadherin: a comparison study with annexin V.
  200. (2004). Measuring circulating cell-derived microparticles.
  201. (2006). Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress.
  202. (2005). Mechanisms for suppressing NADPH oxidase in the vascular wall. Mem Inst Oswaldo Cruz,
  203. (1997). Mechanisms initiating platelet thrombus formation.
  204. (1992). Mechanisms of actin rearrangements mediating platelet activation.
  205. (2008). Mechanisms of Thrombous Formation.
  206. (1978). Membrane and lipid involvement in blood coagulation.
  207. (1977). Membrane asymmetry and blood coagulation.
  208. (2009). Microparticle sizing by dynamic light scattering in fresh-frozen plasma.
  209. (2007). Microparticle-associated tissue factor activity: a link between cancer and thrombosis?
  210. (2008). Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis.
  211. (2007). Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism.
  212. (2001). Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.
  213. (2003). Microparticles in cardiovascular diseases.
  214. (2007). Microparticles in thrombin generation: A signifcant parameter influencing peak thrombin levels.
  215. (2011). Microparticles, malignancy and thrombosis.
  216. (1998). Microvesicle release is associated with extensive protein tyrosine dephosphorylation in platelets stimulated by A23187 or a mixture of thrombin and collagen.
  217. (1998). Mitochondria and apoptosis.
  218. (2003). Mitochondria in cell death: novel targets for neuroprotection and cardioprotection.
  219. (2009). Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore.
  220. (2001). Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential.
  221. (1993). Modulation of platelet function by free radicals and free-radical scavengers.
  222. (1985). Modulation of thrombin-mediated activation of factor VIII:C by calcium ions, phospholipid, and platelets.
  223. (2009). Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed? Thrombosis and Haemostasis,
  224. (1999). Monoclonal antibodies against 276,
  225. (2002). NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment.
  226. (1997). Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation.
  227. (2004). New horizons in the analysis of circulating cell-derived microparticles.
  228. (1992). Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions.
  229. (2001). Nitric oxide inhibition enhances platelet aggregation in experimental anti-Thy-1 nephritis.
  230. (1995). Nitric oxide release from resting human platelets.
  231. (1997). Nitric oxide release in the peripheral blood during hemodialysis.
  232. (1997). Nitric oxide released from activated platelets inhibits platelet recruitment.
  233. (2004). NOX enzymes and the biology of reactive oxygen.
  234. (2006). Nox1-dependent Reactive Oxygen Generation Is Regulated by Rac1.
  235. (2002). Optimized flow cytometric assay for the measurement of platelet microparticles in plasma: pre-analytic and analytic considerations.
  236. (2010). Overcoming limitations of microparticle measurement by flow cytometry.
  237. (2003). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension.
  238. (2000). Oxidative signaling pathway for externalization of plasma membrane phosphatidylserine during apoptosis.
  239. (2005). Oxidative stress in blood platelets from schizophrenic patients.
  240. (2003). Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C. Free Radic Biol Med,
  241. (1997). Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.
  242. (2011). Pathways involved in platelet apoptosis and activation following BCL2-inhibition.
  243. (2003). Peroxynitriteinduced changes of thiol groups in human blood platelets.
  244. (1993). Phagocyte recognition of cells undergoing apoptosis.
  245. (2000). Phenotyping the clotting system.
  246. (1989). Phospholipid binding properties of human placental anticoagulant prtoein-1; a member of the lipocortin family.
  247. (2000). Phospholipid signaling in apoptosis: peroxidation and externalization of phosphatidylserine.
  248. (2010). Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation.
  249. (2009). Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction.
  250. (2004). Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis.
  251. (2002). Platelet activation and blood coagulation.
  252. (1994). Platelet activation by thrombin can be measured in whole blood through the use of the peptide GPRP and flow cytometry methdos and clinical applications.
  253. (1995). Platelet activation: signal transduction via membrane receptors.
  254. (2001). Platelet adhesion enhances the glycoprotein VIdependent procoagulant response:
  255. (2009). Platelet aggregation responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric oxide synthase.
  256. (2002). Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs.
  257. (2010). Platelet formation.
  258. (2008). Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin.
  259. (1999). Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen.
  260. (2001). Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes.
  261. (2002). Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?
  262. (1995). Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.
  263. (2007). Platelet glycoprotein VI-related clinical defects.
  264. (1997). Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.
  265. (1990). Platelet hyperreactivity and prognosis in survivors of myocardial infarction.
  266. (1981). Platelet lipid composition and platelet aggregation in human liver disease.
  267. (1989). Platelet lipid peroxidation in haemodialysis patients: effects of vitamin E supplementation.
  268. (1979). Platelet lipid peroxides as determinant of platelet survival and sympathetic stimulation in patients with hypertension.
  269. (1993). Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA.
  270. (2007). Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets.
  271. (1995). Platelet microparticles bind, activate and aggregate neutrophils in vitro.
  272. (2005). Platelet NAD(P)H-oxidase-generated ROS production regulates {alpha}IIb{beta}3-integrin activation independent of the NO/cGMP pathway.
  273. (2007). Platelet particle formation by anti GPIIIa49-66 Ab, Ca2+ ionophore A23187, and phorbol myristate acetate is induced by reactive oxygen species and inhibited by dexamethasone blockade of platelet phospholipase A2, 12-lipoxygenase, and NADPH oxidase.
  274. (2004). Platelet physiology and thrombosis.
  275. (1991). Platelet procoagulant activity: physiological significance and mechanisms of exposure.
  276. (2010). Platelet reactivity to collagen is diminished in an external reducing environment.
  277. (2008). Platelet receptor redox regulation.
  278. (2010). Platelet receptor signaling in thrombus formation.
  279. (2004). Platelet storage under in vitro condition is associated with calcium-dependent apoptosis-like lesions and novel reorganization in platelet cytoskeleton.
  280. (1978). Platelet survival time: its measurement and use. Prog Hemost Thromb,
  281. (2007). Platelet tissue factor comes of age.
  282. (2001). Platelet transfusion trigger in difficult patients.
  283. (2003). Platelet-collagen interaction: is GPVI the central receptor?
  284. (1993). Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect.
  285. (1996). Platelets and shear stress.
  286. (2002). Platelets and thrombin generation.
  287. (2002). Platelets in atherothrombosis.
  288. (2005). Platelets in inflammation and atherogenesis.
  289. (2000). Platelets release their lysosomal content in vivo in humans upon activation.
  290. (2007). Platelets Structure.
  291. (2007). Platelets. Elsevier/Academic press,
  292. (2011). Pre-analytical and analytical issues in the analysis of blood microparticles.
  293. (2006). Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
  294. (2001). Procoagulant activity on platelets adhered to collagen or plasma clot.
  295. (2006). Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc
  296. (2004). Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence.
  297. (1999). Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction.
  298. (2007). Programmed Anuclear Cell Death Delimits Platelet Life Span.
  299. (1967). Protein synthesis by human platelets.
  300. (2007). Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles.
  301. (2000). Prothrombinase acceleration by oxidatively damaged phospholipids.
  302. (1993). Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.
  303. (2005). Quantitation of microparticles released from coated-platelets.
  304. (2003). Quercetin inhibits collagenstimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway.
  305. (2009). Rapid procoagulant phosphatidylserine exposure relies on high cytosolic calcium rather than on mitochondrial depolarization.
  306. (2003). Reactive oxygen species precede the epsilon isoform of protein kinase C in the anesthetic preconditioning signaling cascade.
  307. (2004). Reactive oxygen species: players in the platelet game.
  308. (2006). Recognition ligands on apoptotic cells: a perspective.
  309. (2009). Recovery and composition of microparticles after snap-freezing depends on thawing temperature.
  310. (2003). Redox control of platelet aggregation.
  311. (2003). Redox state as a central modulator of precursor cell function.
  312. (2008). Reduction in platelet counts as a mechanistic biomarker and guide for adaptive doseescalation in phase I studies of the Bcl-2 family inhibitor ABT-263.
  313. (2004). Regulation of endogenous reactive oxygen species in platelets can reverse aggregation.
  314. (2001). Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1.
  315. (1989). Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin.
  316. (1985). Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombinstimulated human platelets.
  317. (2007). Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy.
  318. (1999). Role of Caspase in a Subset of Human Platelet Activation Responses.
  319. (1994). Role of hydroxyl radicals in the activation of human platelets.
  320. (2002). Role of malondialdehyde-acetaldehyde adducts in liver injury.
  321. (2008). Role of microparticles in atherothrombosis.
  322. (2005). Role of mitochondrial permeability transition pore in coated-platelet formation.
  323. (2006). Role of platelets in the procoagulant environment in blood.
  324. (2009). Role of tissue factor in cancer.
  325. (2009). samples were collected under ethical approval granted by the University of Leicester Research Ethics Committee for a study entitled ‘Studies of
  326. (1979). Secretable storage pools in platelets.
  327. (1982). Selective inhibition of platelet lipoxygenase by baicalein.
  328. (1982). Selective inhibition of platelet lipoxygenase by esculetin.
  329. (2007). Serpins in thrombosis, hemostasis and fibrinolysis.
  330. (2002). Shear stressinduced aggregation of oxidized platelets.
  331. (1994). Shear-stress-induced von Willebrand factor binding to platelets causes the activation of tyrosine kinase(s).
  332. (1999). Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity.
  333. (1998). Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets.
  334. (2000). Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha IIbbeta 3 activation both in platelets and a transfected Chinese hamster ovary cell system.
  335. (1999). Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIMkinase.
  336. (1992). Social controls on cell survival and cell death.
  337. (1991). Some properties of rat platelet aggregation and effects of butylated hydroxytoluene, warfarin and aspirin.
  338. (1994). Spectral characterization of lipid peroxidation in rabbit lens membranes induced by hydrogen peroxide in the presence of Fe2+/Fe3+ cations: a site-specific catalyzed oxidation.
  339. (1991). Spectroscopic detection of lipid peroxidation products and structural changes in a sphingomyelin model system.
  340. (1999). Standardisation and optimisation of experimental conditions to allow analysis and measurement of intracellular oxidative stress in platelets, monocytes and plateletmonocyte aggregates. MSc thesis,
  341. (2010). Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of
  342. (2010). Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop.
  343. (2006). Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI.
  344. (2000). Structural basis of collagen recognition by integrin alpha2beta1.
  345. (1986). Structure, function, and molecular defects of factor IX.
  346. (1998). Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles.
  347. (2007). Studies on free radicals, antioxidants, and co-factors.
  348. (1983). Studies with a
  349. (1999). Suicidal tendencies: apoptotic cell death by caspase family proteinases.
  350. (2000). Superoxide anion and hydroxyl radical release by collagen-induced platelet aggregation--role of arachidonic acid metabolism.
  351. (1977). Superoxide production and reducing activity in human platelets.
  352. (1996). Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus.
  353. (2000). Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin.
  354. (2004). Surface Expression of Collagen Receptor Fc ReceptorÎ/Glycoprotein
  355. (1990). Surface-dependent reactions of the vitamin K-dependent enzyme complexes.
  356. (2004). Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus.
  357. (1997). Sustained Platelet Glycoprotein IIb/IIIa Blockade With Oral Xemilofiban in 170 Patients After Coronary Stent Deployment.
  358. (1976). The activation of bovine coagulation factor X.
  359. (1963). The Aggregation of Blood Platelets.
  360. (2009). The cell-based model of coagulation.
  361. (2008). The characterization and impact of microparticles on haemostasis within fresh-frozen plasma.
  362. (1991). The coagulation cascade: initiation, maintenance, and regulation.
  363. (1979). The contribution of bovine Factor V and Factor Va to the activity of prothrombinase.
  364. (1984). The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation Factor X by activated Factor IX.
  365. (2003). The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion.
  366. (1969). The dense bodies of human platelets: inherent electron opacity of the serotonin storage particles.
  367. (1987). The effect of thrombin on the complex between factor VIII and von Willebrand factor.
  368. (2003). The evolving role of platelets in inflammation.
  369. (1997). The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen.
  370. (2001). The generation of superoxide anion in blood platelets in response to different forms of Proteus mirabilis lipopolysaccharide: effects of staurosporin, wortmannin, and indomethacin.
  371. (1994). The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin.
  372. (2008). The lipid whisker model of the structure of oxidized cell membranes.
  373. (2003). The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression.
  374. (2000). The mechanism of apoptosis in human platelets during storage.
  375. (1998). The mechanisms of action of alpha- and beta-isoforms of antithrombin.
  376. (2005). The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality.
  377. (1996). The molecular biology of apoptosis.
  378. (1998). The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin.
  379. (1999). The Platelet Collagen Receptor Glycoprotein VI Is a Member of the Immunoglobulin Superfamily Closely Related to FcαR and the Natural Killer Receptors.
  380. (2005). The platelet microparticle proteome.
  381. (2000). The protein C pathway.
  382. (1989). The reassociation of factor Va from its isolated subunits.
  383. (2009). The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease.
  384. (2001). The role of ITAM- and ITIM-coupled receptors in platelet activation by collagen.
  385. (1992). The roles of fibrinogen and fibrin in hemostasis and thrombosis.
  386. (1997). The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thrombosis and Haemostasis,
  387. (1999). The von Willebrand factorglycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IXtransfected cells.
  388. (1999). Thrombin activates factor XI on activated platelets in the absence of factor XII.
  389. (2000). Thrombin facilitates primary platelet adhesion CH 9: References onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions.
  390. (2005). Thrombin generation and phenotypic correlation in haemophilia A.
  391. (2008). Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
  392. (2008). Thrombin induces activation and translocation of Bid, Bax and Bak to the mitochondria in human platelets.
  393. (1982). Thrombin-catalyzed activation of human coagulation factor V.
  394. (1987). Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex.
  395. (2002). Thrombin-induced platelet microparticles improved the aggregability of cryopreserved platelets.
  396. (2006). Thrombin-triggered platelet apoptosis.
  397. (2003). Thrombininduced conversion of fibrinogen to fibrin results in rapid platelet CH 9: References trapping which is not dependent on platelet activation or GPIb.
  398. (2010). Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program,
  399. (2001). Thrombogenic role of cells undergoing apoptosis.
  400. (2009). Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost,
  401. (2007). Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.
  402. (2003). Tissue factor, thrombin, and cancer.
  403. (2004). Tissue factor: (patho)physiology and cellular biology.
  404. (2005). Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay.
  405. (1997). Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles.
  406. (2000). Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.
  407. (2002). Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P.
  408. (1996). Transmission of a procoagulant signal from tissue factor-bearing cell to platelets.
  409. (2007). Treatment with aspirin and clopidogrel inhibit thrombin generation in patinetss with stable coronory artery disease. Joirnal of thrombosis and haemostasis,
  410. (2009). Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function.
  411. (2001). Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib.
  412. (1989). Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets.
  413. (1990). Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa.
  414. (1992). Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells.
  415. (1996). Variability in platelet procogaulant activity in healthy volunteer.
  416. (2002). Vav1, but not Vav2, contributes to platelet aggregation by CRP and thrombin, but neither is required for regulation of phospholipase
  417. (2003). Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects.
  418. (1991). von Willebrand factor binding to platelet GpIb initiates signals for platelet activation.
  419. (2003). Von Willebrand factor, platelets and endothelial cell interactions.
  420. (1964). Waterfall sequence for intrinsic blood clotting.
  421. (2002). Weak platelet agonists and U46619 induce apoptosis-like events in platelets, in the absence of phosphatidylserine exposure.
  422. (1996). Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.